Assessment of methotrexate hepatotoxicity in psoriasis patients: A prospective evaluation of four serum fibrosis markers

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 8, 2013, Pages 1007-1014

  Chladek J ^a   Simkova M ^b   Vaneckova J ^b   Hroch, M ^a   Vavrova J ^b   Hulek P ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; HYALURONIC ACID; METHOTREXATE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; RETINOID;

ADULT; AGED; ARTICLE; BODY MASS; BODY SURFACE; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER FIBROSIS; LIVER TOXICITY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; REMISSION; RISK ASSESSMENT; SYSTEMIC THERAPY; TREATMENT DURATION;

ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; FIBROSIS; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS;

EID: 84880513232     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04643.x     Document Type: Article

References (25)

1. Montaudié H, Sbidian E, Paul C, et al. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol 2011; 25 (Suppl 2): 12-18.
2. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl 2): 1-70.
3. Chládek J, Grim J, Martínková J, et al. Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. Br J Clin Pharmacol 2002; 54: 147-156.
4. Hroch M, Chladek J, Simkova M, et al. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. J Eur Acad Dermatol Venereol 2008; 22: 19-24.
5. Chládek J, Vaněčková J, Šimková M, et al. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur J Clin Pharmacol 2008; 64: 347-355.
6. Barker J, Horn EJ, Lebwohl M, et al. International Psoriasis Council. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol 2011; 25: 758-764.
7. Manning DS, Afdhal NH,. Diagnosis and quantitation of fibrosis. Gastroenterology 2008; 134: 1670-1681.
8. Berends MA, Snoek J, de Jong EM, et al. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. Liver Int 2007; 27: 639-645.
9. Laharie D, Seneschal J, Schaeverbeke T, et al. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study. J Hepatol 2010; 53: 1035-1040.
10. Chladek J, Grim J, Martinkova J, et al. Low-dose methotrexate pharmacokinetics and pharmacodynamics in the therapy of severe psoriasis. Basic Clin Pharmacol Toxicol 2005; 96: 247-248.
11. Hroch M, Tuková J, Dolezalová P, Chládek J,. An improved high-performance liquid chromatography method for quantification of methotrexate polyglutamates in red blood cells of children with juvenile idiopathic arthritis. Biopharm Drug Dispos 2009; 30: 138-148.
12. Adams LA, Bulsara M, Rossi E, et al. Hepascore. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51: 1867-1873.
13. Stickel F, Poeschl G, Schuppan D, et al. Serum hyaluronate correlates with histological progression in alcoholic liver disease. Eur J Gastroenterol Hepatol 2003; 15: 945-950.
14. McHutchison JG, Blatt LM, de Medina M, et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol 2000; 15: 945-951.
15. Wells AF, Lundin Å, Michaësson G,. Histochemical localization of hyaluronan in psoriasis, allergic contact dermatitis and normal skin. Acta Derm Venereol 1991; 71: 232-238.
16. Emlen W, Niebur J, Flanders G, Rutledge J,. Measurement of serum hyaluronic acid in patients with rheumatoid arthritis: correlation with disease activity. J Rheumatol 1996; 23: 974-978.
17. Goldberg RL, Huff JP, Lenz ME, et al. Elevated plasma levels of hyaluronate in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 1991; 34: 799-807.
18. Lundin A, Engström-Laurent A, Hällgren R, Michaëlsson G,. Circulating hyaluronate in psoriasis. Br J Dermatol 1985; 112: 663-671.
19. Elkayam O, Yaron I, Shirazi I, et al. Serum levels of hyaluronic acid in patients with psoriatic arthritis. Clin Rheumatol 2000; 19: 455-457.
20. Zachariae H, Heickendorff L, Søgaard H,. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Br J Dermatol 2001; 144: 100-103.
21. Hertel NT, Stoltenberg M, Juul A, et al. Serum concentrations of type I and III procollagen propeptides in healthy children and girls with central precocious puberty during treatment with gonadotropin-releasing hormone analog and cyproterone acetate. J Clin Endocrinol Metab 1993; 76: 924-927.
22. Anttila P, Järvi K, Latvala J, et al. Biomarkers of alcohol consumption in patients classified according to the degree of liver disease severity. Scand J Clin Lab Invest 2005; 65: 141-151.
23. Maurice PD, Maddox AJ, Green CA, et al. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen. Br J Dermatol 2005; 152: 451-458.
24. Ameglio F, Bonifati C, Carducci M, et al. Soluble intercellular adhesion molecule-1 and procollagen III peptide are reliable markers of disease severity in psoriasis. Acta Derm Venereol Suppl (Stockh) 1994; 186: 19-20.
25. Poynard T, Munteanu M, Deckmyn O, et al. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age. BMC Gastroenterol 2011; 11: 39.